| DAY 1 - Aug. 26(Thu.) | Channel A | Channel B | Channel C | Channel D |
|---|---|---|---|---|
| 09:00-09:30 | ICBMT 2021 Virtual Opening Ceremony | |||
| 09:30-10:30 | Plenary 1 Genomics in transplantation |
|||
| 10:30-10:40 | Break | |||
| 10:40-11:10 | Plenary 2 State of the art in CAR-T cell therapy |
|||
| 11:10-11:20 | Break | |||
| 11:20-12:20 | Plenary 3 Data science for research in HCT |
|||
| 12:20-12:40 | Break | |||
| 12:40-13:20 | Industry Symposium 1 |
Industry Symposium 2  |
Industry Symposium 3  |
Industry Symposium 4  |
| 13:20-13:30 | Break | |||
| 13:30-14:30 | Oral 1 | Oral 2 | Oral 3 | Oral 4 |
| 14:30-14:40 | Break | |||
| 14:40-16:10 | Scientific Session 1 The road to genomics enlightening the acute leukemia with or without BMT |
Joint Symposium 1 JSTCT-KSBMT Complication management after Allo-HSCT |
Education Session 1 Critical post-transplantation complications |
Nursing Session 1Kor. |
| 16:10-16:20 | Break | Break | Break | |
| 16:20-16:30 | Break | Joint Symposium 2 EBMT-KSBMT Paradigm shift in Hodgkin lymphoma; Bridging therapy to allo-HSCT (novel agent before and after allo-HSCT) and PTCy in Haplo-HSCT |
||
| 16:30-18:00 | Scientific Session 2 Maintenance treatment strategies after allogeneic HSCT in the novel agent era |
Scientific Session 3 Pediatric ALL |
Case Discussion 1&2Kor. (16:30-18:00) |
|
| 18:00-18:10 | Break | |||
| 18:10-18:40 | Poster 1 | Poster 2 | Poster 3 | Poster 4 |
| DAY 2 - Aug. 27(Fri.) | Channel A | Channel B | Channel C | Channel D |
|---|---|---|---|---|
| 09:00-10:30 | Scientific Session 4 High risk multiple myeloma |
Joint Symposium 3 ASTCT-KSBMT Minimal residual disease in allogeneic HCT or cellular therapy |
Scientific Session 5 HSCT in pediatric non-malignant disease (09:00-11:00) |
Education Session 2 Kor. Long term management of allogeneic stem cell transplant recipients |
| 10:30-10:40 | Break | Break | Break | |
| 10:40-10:50 | ||||
| 10:50-12:20 | Scientific Session 6 New and emerging therapeutics for acute and chronic GVHD |
Education Session 3 HSCT in rare hematologic malignancies |
Break | Joint Symposium 4 ISCT-KSBMT Advances in biology and clinical application of cellular therapy: CAR-T therapy in solid malignancy |
| Industry Symposium 5 (11:40~12:20) 
| ||||
| 12:20-12:30 | Break | |||
| 12:30-13:10 | Industry Symposium 6 |
Industry Symposium 7 |
Industry Symposium 8 |
Industry Symposium 9 |
| 13:10-13:20 | Break | |||
| 13:20-14:20 | Oral 5 | Oral 6 | Oral 7 | Oral 8 |
| 14:20-14:30 | Break | |||
| 14:30-15:10 | Presidential Symposium | |||
| 15:10-15:20 | Break | |||
| 15:20-16:50 | Scientific Session 7 Cell therapy I (non CAR-T) |
Scientific Session 8 Alternative donor transplant for SAA |
Education Session 4 Advances in the laboratory medicine |
Education Session 5Kor. Statistics in HSCT |
| 16:50-17:00 | Break | |||
| 17:00-18:00 | Oral 9 | Oral 10 | Oral 11 | Oral 12 |
| 18:00-18:10 | Break | |||
| 18:10-18:40 | Poster 5 | Poster 6 | Poster 7 | Poster 8 |
| DAY 3 - Aug. 28 (Sat.) | Channel A | Channel B | Channel C | Channel D |
|---|---|---|---|---|
| 07:30-09:00 | KSBMT Business Meeting | |||
| 09:00-10:30 | Scientific Session 9 Cell therapy II (CAR-T) |
Scientific Session 10 The role of stem cell transplantation in lymphoma in the era of novel and cell therapy |
Scientific Session 11 Best donor for allogeneic HSCT: beyond matched sibling donor |
Nursing Session 2 Kor. |
| 10:30-10:40 | Break | |||
| 10:40-12:10 | Scientific Session 12 Donor lymphocyte infusion after HSCT |
Scientific Session 13 Advancing science together for a better future of HSCT |
Joint Symposium 5 TSBMT-KSBMT Second malignancies after Allo-HSCT & Auto-HSCT |
Student/Resident LectureKor. |
| 12:10-12:20 | Break | |||
| 12:20-12:30 | Closing Ceremony | |||
| 12:30-13:00 | ICBMT General Assembly | |||
